Pharmacokinetic and Imaging Studies of Liposome-Associated Adriamycin
Author Information
Author(s): A. Gabizon, R. Chisin, S. Amselem, S. Druckmann, R. Cohen, D. Goren, I. Fromer, T. Peretz, A. Sulkes, Y. Barenholz
Primary Institution: Hadassah Medical Center; Hebrew University-Hadassah Medical School
Hypothesis
The study investigates the pharmacokinetics and imaging characteristics of liposome-entrapped adriamycin in cancer patients.
Conclusion
The study found that liposome-associated adriamycin is rapidly cleared from plasma, with significant variability in clearance rates among patients.
Supporting Evidence
- Liposome-associated drug was rapidly cleared from plasma, correlating with liver function.
- Imaging studies showed predominant clearance of liposomes by the liver and spleen.
- Patients with liver dysfunction exhibited decreased liver clearance and increased bone marrow uptake.
- Significant variability in pharmacokinetic parameters was observed among patients.
Takeaway
This study looked at how a special form of cancer medicine is processed in the body, showing it leaves the bloodstream quickly and behaves differently depending on the patient's liver health.
Methodology
The study involved pharmacokinetic analysis and imaging studies in patients receiving liposome-entrapped adriamycin during a Phase I clinical trial.
Limitations
The study noted significant interpatient variability in drug clearance and limited uptake in tumors, which may affect the generalizability of the results.
Participant Demographics
Patients included in the study had varying liver functions, with some suffering from liver dysfunction.
Want to read the original?
Access the complete publication on the publisher's website